Clinical outcomes of epidermal growth factor receptor tyrosine kinase inhibitors in recurrent adenosquamous carcinoma of the lung after resection

Figures & data

Table 1 Clinical characteristics of patients with adenosquamous carcinoma of the lung

Variables	N=27	%
Gender
Male	11	40.7
Female	16	59.3
PS
1	15	55.6
2	12	44.4
Age
≤54	14	51.9
>54	13	48.1
Smoking
Yes	7	25.9
No	20	74.1
Resection
Wedge resection	3	11.1
Lobectomy	13	48.2
Extended resection	11	40.7
Sleeve resection	2
Lobectomy + wedge resection	1
Bilobectomy	4
Pneumonectomy	4
TNM stage
IA	1	3.7
IB	1	3.7
IIA	1	3.7
IIB	1	3.7
IIIA	19	70.4
IIIB	1	3.7
IV	3	11.1

Abbreviations: PS, performance status; TNM, tumor, node, and metastases.

Figure 1 Progression-free survival of patients with ASC of the lung (A), and subgroup analysis for patients from groups 1 and 2 (B). Note: Group 1, patients with local recurrence; group 2, patients with metastasis.

Abbreviation: ASC, adenosquamous carcinoma.

Figure 2 Postoperative overall survival of patients with ASC of the lung (A), and subgroup analysis for patients from groups 1 and 2 (B). Note: Group 1, patients with local recurrence; group 2, patients with metastasis.

Abbreviation: ASC, adenosquamous carcinoma.

Figure 3 Relapse overall survival of patients with ASC of the lung (A), and subgroup analysis for patients from groups 1 and 2 (B). Note: Group 1, patients with local recurrence; group 2, patients with metastasis.

Abbreviation: ASC, adenosquamous carcinoma.